Vaccination

Originally approved by the FDA in 2006, the vaccine prevents certain cancers and diseases caused by the 9 types of HPV covered by the vaccine—an expansion from its originally-approved prevention of 4 different types.

High-risk individuals, such as those with cardiopulmonary and other chronic conditions, are protected from flu-related hospitalizations with the vaccine.

An oral influenza vaccine tablet protects against virus as well or better than an injectable quadrivalent vaccine in phase 2 trial.

Updates in trivalent vaccines and vaccination clearance for egg-allergic patients were among the updated recommendations for pediatric influenza prevention and treatment this upcoming 2018-2019 flu season.

Less than one-third received both influnza and Tdap vaccination during their pregnancies, citing limited understanding or assurance of their benefits and safety.

Tumor regressions were observed in 2 of the first 4 evaluable patients in the ongoing phase 2 trial evaluating DPX-Survivac in combination with low dose cyclophosphamide and pembrolizumab.

Investigators found that active choice intervention correlated with a nearly 10% increased likelihood of patients receiving the seasonal flu vaccine.

New recommendations from the CDC's Advisory Committee on Immunization Practices reveal that health care providers have the intranasally-administered live attenuated influenza vaccine (LAIV) among their arsenal of available vaccines for the 2018-2019 flu season.

In a systematic review and meta-analysis, low-quality drugs are most prevalent low- to middle-income countries, and can cost up to $200 billion annually.

First-in-man phase 1 trial meets its primary endpoints by demonstrating safety and immunogenicity of a mutation-specific IDH1R132H peptide vaccine.

Roche's cobas test systems will now be able to screen multiple individual blood or plasma donations that have been pooled together.

The U.S. FDA has granted Fast Track designation to PaxVax for development of its vaccine for prevention of the chkungunya virus.

Researchers continue to seek means to improve the efficacy and tolerability of the RTS,S vaccine.

Paul Ananth Tambyah, MD, Dept. of Medicine, Infectious Disease, National University of Singapore, provides an overview of infection control approach for travelers with either epidemic or endemic diseases from various parts of the world.

The Canadian-based pharmaceutical company plans to produce a low-cost, multi-strain coverage vaccine with the grant.

In at least one particular vaccine, the national rate of initial dose was greater than 80%. The rate to take the booster dose was less than 40%.

The CDC-based study sought to combat influenza epidemic risks with an earlier jump on outbreak detection.

The investigational hepatitis-B drug has been rejected for approval twice in the past 3 years, but creator Dynavax Technologies still hopes for an early 2018 US commercial release.

Trials hold enormous potential, but could take a decade or more to complete.

The to-be-acquired Protein Sciences had received US Food and Drug Administration approval for their Flublok Quadrivalent Influenza Vaccine in October 2016.

With major progress in daily treatments, one expert believes a cure could be a decade away.

CDC task force has recommended not using LAIV (nasal spray) for influenza prevention.

CDC's Advisory Committee on Immunization Practices (ACIP) are published for the current US influenza season.

HPV is apparently on the rise in the United States among unvaccinated adults.

Hepatitis C mutations help the virus dodge vaccines.

Jared Ditkowsky, MD, SUNY Downstate, explained the connotations surrounding the development of a potential vaccine for Chlamydia trachomatis (C. trachomatis), the infection causing chlamydia - one of the most common bacterial sexually transmitted infections in the United States.

Jared Ditkowsky, MD candidate, SUNY Downstate explained that many of the problems surrounding a potential chlamydia vaccine are immunologic in nature.

Glioblastoma is a deadly brain tumor. Vaccines look promising.

The NIAID is enrolling participants to receive two AGS-v injections.

HIV-positive men who have sex with men or women are at risk for HPV.